Forskning ved Københavns Universitet - Københavns Universitet

Forside

When, for whom and how to use sibutramine?

Publikation: Bidrag til tidsskriftKonferenceartikelForskningfagfællebedømt

Standard

When, for whom and how to use sibutramine? / Astrup, Arne; Toubro, Søren.

I: International Journal of Obesity, Bind 25, Nr. Suppl. 4, 2001, s. S2-S7.

Publikation: Bidrag til tidsskriftKonferenceartikelForskningfagfællebedømt

Harvard

Astrup, A & Toubro, S 2001, 'When, for whom and how to use sibutramine?', International Journal of Obesity, bind 25, nr. Suppl. 4, s. S2-S7. https://doi.org/10.1038/sj.ijo.0801930

APA

Astrup, A., & Toubro, S. (2001). When, for whom and how to use sibutramine? International Journal of Obesity, 25(Suppl. 4), S2-S7. https://doi.org/10.1038/sj.ijo.0801930

Vancouver

Astrup A, Toubro S. When, for whom and how to use sibutramine? International Journal of Obesity. 2001;25(Suppl. 4):S2-S7. https://doi.org/10.1038/sj.ijo.0801930

Author

Astrup, Arne ; Toubro, Søren. / When, for whom and how to use sibutramine?. I: International Journal of Obesity. 2001 ; Bind 25, Nr. Suppl. 4. s. S2-S7.

Bibtex

@inproceedings{d9018fb6dd8947428b118cf9b7fbbd7c,
title = "When, for whom and how to use sibutramine?",
abstract = "Sibutramine is the first of a new generation of weight management drugs, and offers long-term control of weight when used as an adjunct to diet and exercise. This paper considers the criteria set down by the European Union's regulatory agency for its use and how this relates to the information now available on its efficacy, side-effect profile and benefits in different patient groups. The data presented relate to 18-65y olds; its use in other age groups has not been established. The EU licence permits continuous treatment for periods of up to 1y; the STORM study has now led the US Food and Drug Administration to extend clearance to 2y. The addition of sibutramine to a regimen of diet, exercise and lifestyle modification results in 3-5 times more patients responding to a weight-reduction programme, ie achieving more than 5{\%} weight maintenance. Sibutramine is indicated for use in obese patients (BMI > 30 kg/m2) and also overweight patients with a BMI > 27 kg/m2 who have additional obesity-related risk factors such as type 2 diabetes or dyslipidaemia.",
keywords = "Comorbid obesity, Sibutramine, Sustained efficacy, Weight loss",
author = "Arne Astrup and S{\o}ren Toubro",
year = "2001",
doi = "10.1038/sj.ijo.0801930",
language = "English",
volume = "25",
pages = "S2--S7",
journal = "International Journal of Obesity",
issn = "0307-0565",
publisher = "nature publishing group",
number = "Suppl. 4",

}

RIS

TY - GEN

T1 - When, for whom and how to use sibutramine?

AU - Astrup, Arne

AU - Toubro, Søren

PY - 2001

Y1 - 2001

N2 - Sibutramine is the first of a new generation of weight management drugs, and offers long-term control of weight when used as an adjunct to diet and exercise. This paper considers the criteria set down by the European Union's regulatory agency for its use and how this relates to the information now available on its efficacy, side-effect profile and benefits in different patient groups. The data presented relate to 18-65y olds; its use in other age groups has not been established. The EU licence permits continuous treatment for periods of up to 1y; the STORM study has now led the US Food and Drug Administration to extend clearance to 2y. The addition of sibutramine to a regimen of diet, exercise and lifestyle modification results in 3-5 times more patients responding to a weight-reduction programme, ie achieving more than 5% weight maintenance. Sibutramine is indicated for use in obese patients (BMI > 30 kg/m2) and also overweight patients with a BMI > 27 kg/m2 who have additional obesity-related risk factors such as type 2 diabetes or dyslipidaemia.

AB - Sibutramine is the first of a new generation of weight management drugs, and offers long-term control of weight when used as an adjunct to diet and exercise. This paper considers the criteria set down by the European Union's regulatory agency for its use and how this relates to the information now available on its efficacy, side-effect profile and benefits in different patient groups. The data presented relate to 18-65y olds; its use in other age groups has not been established. The EU licence permits continuous treatment for periods of up to 1y; the STORM study has now led the US Food and Drug Administration to extend clearance to 2y. The addition of sibutramine to a regimen of diet, exercise and lifestyle modification results in 3-5 times more patients responding to a weight-reduction programme, ie achieving more than 5% weight maintenance. Sibutramine is indicated for use in obese patients (BMI > 30 kg/m2) and also overweight patients with a BMI > 27 kg/m2 who have additional obesity-related risk factors such as type 2 diabetes or dyslipidaemia.

KW - Comorbid obesity

KW - Sibutramine

KW - Sustained efficacy

KW - Weight loss

U2 - 10.1038/sj.ijo.0801930

DO - 10.1038/sj.ijo.0801930

M3 - Conference article

C2 - 11916101

AN - SCOPUS:0035698501

VL - 25

SP - S2-S7

JO - International Journal of Obesity

JF - International Journal of Obesity

SN - 0307-0565

IS - Suppl. 4

ER -

ID: 209780678